Syneos Health : 2022 Baird Global Healthcare Conference Presentation –

Syneos Health : 2022 Baird Global Healthcare Conference Presentation –

2022 Annual Baird Global Healthcare Conference
Michelle Keefe, CEO
Jason Meggs, CFO
September 13, 2022
Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this presentation are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including the future impact of the COVID-19 pandemic, inflation, and the war between Russia and Ukraine on our business, financial results and financial condition, expected interest rates, anticipated financial results including book-to-bill outlook, our sales pipeline, existing backlog and expectations of net awards, expected non-GAAP tax rate, trends in reimbursable out-of-pocket expenses, benefits of recent acquisitions, and plans for capital deployment. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: risks associated with the COVID-19 pandemic; the Company’s potential failure to generate a large number of new business awards and the risk of delay, termination, reduction in scope, or failure to go to contract of our
business awards; the Company’s potential failure to convert backlog to revenue; fluctuations in the Company’s operating results and effective income tax rate; the impact of potentially underpricing the Company’s contracts, overrunning our cost estimates, or failing to receive approval for or experiencing delays with documentation of change orders; cyber-security and other risks associated with the Company’s information systems infrastructure; changes and costs of compliance with regulations related to data privacy; concentration of the Company’s customers or therapeutic areas; the risks associated with doing
business internationally, including risks related to the war in Ukraine; challenges
by tax authorities of the Company’s intercompany transfer pricing policies; the Company’s potential failure to successfully increase its market share, grow its business, and execute its growth strategies; the Company’s ability to effectively upgrade its information systems; the Company’s failure to perform its services in
accordance with contractual requirements, regulatory standards, and ethical considerations; risks related to the management of clinical trials; the need to hire, develop, and retain key personnel; the impact of unfavorable economic conditions, including the uncertain international economic environment, changes in foreign currency exchange rates; effective income tax rate fluctuations; the Company’s ability to protect its intellectual property; risks related to the
Company’s acquisition strategy, including its ability to realize synergies; the Company’s relationships with customers who are in competition with each other; any failure to realize the full value of the Company’s goodwill and intangible assets; risks related to restructuring; the Company’s compliance with anti- corruption and anti-bribery laws; the Company’s dependence on third parties; potential employment liability; impacts from increasing focus on environmental sustainability and social initiatives; the Company’s ability to utilize net operating loss carryforwards and other tax attributes; downgrades of the Company’s credit
ratings; competition in the biopharmaceutical services industry; outsourcing trends and changes in aggregate spending and research and development budgets; the impact of, including changes in, government regulations and healthcare reform; intense competition faced by our customers from lower cost generic products and other competing products; the Company’s ability to keep pace with rapid technological change; the cost of and the Company’s ability to service its substantial indebtedness; other risks related to ownership of the Company’s common stock; and other risk factors set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as updated by the Company’s other SEC filings, copies of which are available free of charge on the Company’s website at The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
© 2022 Syneos Health®. All rights reserved. Authorized use only.
SYNH: The Only Fully Integrated Biopharmaceutical Solutions Organization Purpose Built to Accelerate Customer Success
Increasingly Complex Environment Requires Innovative Solutions
Scientific and Regulatory Complexity
Targeted Patient Populations
Patient-Centric Approach
Higher-Cost Therapies
Market Access Hurdles
Value and Access
DCT and Home Health Care
Fit for Purpose
Accelerating trials in C&GT/complex modalities
Manage Complex Modalities
© 2022 Syneos Health®. All rights reserved. Authorized use only.
Update on Key Growth Drivers
Current Clinical
YTD Highlights
Large Pharma
SMID & Emerging Biopharma
Clinical Book-to-Bill Outlook
Anticipate TTM Book-to-Bill for Q3 2022 to be in the range of 1.05x – 1.15x 3
© 2022 Syneos Health®. All rights reserved. Authorized use only.
Investing to Enhance Operating Model & Customer Engagement
Clinical Reimagined

Post-COVIDtech-enabled model, optimizing local country capabilities and resources Investing in complex development areas (e.g., C&GT) and FSP capabilities Enhanced scalability to support additional large pharma penetration
Integrating Medical Affairs & Commercial solutions earlier into clinical development
Business Development

Sophisticated customer engagement through strategic solution design and enhanced service approach
Reorganization of key customer-facing roles across segments
Enhanced geographic footprint in critical biotech corridors around the globe
Technology & Data

Predictive analytics supporting country and site selection, patient recruitment and enrollment, and site activation
Advanced data science AI-based applications through RXDataScience Early signal detection and intervention
Optimized resource deployment Unified, cloud-based ERP
© 2022 Syneos Health®. All rights reserved. Authorized use only.
This is an excerpt of the original content. To continue reading it, access the original document here.
Syneos Health Inc. published this content on 13 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 September 2022 10:19:00 UTC.


Leave a Comment

Leave a Reply

Your email address will not be published.

The Devil Really is in the Details: The SEC Proposed Rule on Cybersecurity Risk Management for Investment Advisors, Registered Investment Companies and BDCs – JD Supra

'We don't know what happened': Cyber security expert says WRDSB needs to be more transparent over data hack – CTV News Kitchener

Cyber security at sea: a brand new naval cyber framework – Thales

Transit Is Seeing More Cyber Threats, Many Agencies Aren’t Ready – Government Technology